Repository logo

Browsing by Issue Date, starting with "2024-05-07"

Filter results by year or month
Now showing 1 - 2 of 2
  • Hotel demand forecasting models and methods using artificial intelligence: a systematic literature review
    Publication . Henriques, Henrique; Pereira, Luis Nobre; Henriques, Henrique; Nobre Pereira, Luis
    This systematic literature review (SLR) explores current state-of-the-art artificial intelligence (AI) methods for forecasting hotel demand. Since revenue management (RM) is crucial for business success in the hotel industry, this study aims to identify state-of-the-art effective AI -based solutions for hotel demand forecasting, including machine learning (ML), deep learning (DP), and artificial neural networks (ANNs). The study conducted an SLR using the PRISMA model and identified 20 papers indexed in Scopus and the Web of Science. It addresses the gaps in the literature on AI -based demand forecasting, highlighting the need for clarity in model specification, understanding the impact of AI on pricing accuracy and financial performance, and the challenges of available data quality and computational expertise. The review concludes that AI technology can significantly improve forecasting accuracy and empower data -driven decisions in hotel management. Additionally, this study discusses the limitations of AI -based demand forecasting, such as the need for high -quality data. It also suggests future research directions for further enhancing AI forecasting techniques in the hospitality industry.
    2024-05-07Journal article Open access Show more
  • Treatment options for refractory ulcerative colitis: Small molecules, big effects
    Publication . Marafini, Irene; Roseira, Joana; Duijvestein, Marjolijn
    Although the majority of patients with ulcerative colitis (UC) have a mild-to-moderate disease, approximately 10%–15% experience a severe disease course and require immunosuppressive therapies.1 A better understanding of the mechanisms sustaining the pathogenic process in inflammatory bowel diseases (IBD) has largely contributed to expand the therapeutic armamentarium for this group of patients. Alongside with conventional therapies, monoclonal antibodies against tumour necrosis factor-α, α4β7 integrin (vedolizumab), interleukin (IL)-12/IL-23 p40 subunit (ustekinumab), and small molecules inhibiting intracellular pathways downstream to cytokine receptors (tofacitinib, filogotinib and upadacitinib), have entered into the clinic for the treatment of UC.2 However, selecting the appropriate medical therapy for each patient at a given stage of the disease natural history is an increasingly complex task for clinicians, as no prediction for treatment effect can be made in the individual patient.
    2024-05-07Journal article Open access Show more